Arianne Morissette

During my MSc and PhD studies, I focused on the interplay between dietary interventions, gut microbiota composition, and the risk of cardiometabolic diseases associated with obesity, such as type 2 diabetes and liver disease. Utilizing both preclinical and clinical models, I published three original research articles and one scientific review as the first author. Additionally, I have three manuscripts currently under review, showcasing my high productivity and autonomy in research. As a Grants Officer, I used my deep understanding of the research funding landscape to assist researchers in obtaining funding through various granting agencies. I then joined Dr. Erin Mulvihill's lab as a project manager, where I assisted in securing funding, led multidisciplinary projects focused on the role of incretin hormones in type 2 diabetes and obesity management and published 3 scientific reviews. Skilled in both French and English, ensuring compliance and efficiency in high-stakes environments.

• 3-month Research Internship in Lyon, France in 2016 in the Laboratory of Dr. Martine Laville where I contributed to the validation and optimization of a smart, multisensory cardio-metabolic risk monitoring system called the Wize Mirror with an international team of collaborators
• 3-month Research Internship in Brussels, Belgium in 2019 in the Laboratory of Dr. Patrice Cani where I contributed to exploring the cardiometabolic effects of supplementing various dietary supplements to an obesogenic diet

• Registered Dietitian (#14892). College of Dietitians of Ontario
• Project Management Certification exam prep to be completed in June 2024.

Published Manuscripts

1. Morissette A, Daniel N, Marette A. Yaourt et santé cardio-métabolique. Médecine des Maladies Métaboliques. 2020;14(8):692-8. doi: 10.1016/j.mmm.2020.10.012.

2. Morissette A, Kropp C, Songpadith JP, Junges Moreira R, Costa J, Marine-Casado R, et al. Blueberry proanthocyanidins and anthocyanins improve metabolic health through a gut microbiota-dependent mechanism in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2020;318(6):E965-E80. Epub 20200331. doi: 10.1152/ajpendo.00560.2019. PubMed PMID: 32228321.

3. Régnier M, Rastelli M, Morissette A, Suriano F, Le Roy T, Pilon G, et al. Rhubarb Supplementation Prevents Diet-Induced Obesity and Diabetes in Association with Increased Akkermansia muciniphila in Mice. Nutrients. 2020;12(10). doi: 10.3390/nu12102932.

4. Morissette A, Andre DM, Agrinier AL, Varin TV, Pilon G, Flamand N, et al. The metabolic benefits of substituting sucrose for maple syrup are associated with a shift in carbohydrate digestion and gut microbiota composition in high-fat high-sucrose diet-fed mice. Am J Physiol Endocrinol Metab. 2023;325(6):E661-E71. Epub 20231025. doi: 10.1152/ajpendo.00065.2023. PubMed PMID: 37877794.

5. Gignac T, Trepanier G, Pradeau M, Morissette A, Agrinier AL, Larose E, et al. Metabolic-Associated Fatty Liver Disease is Characterized by a Post-Oral Glucose Load Hyperinsulinemia in Individuals with Mild Metabolic Alterations. Am J Physiol Endocrinol Metab. 2024. Epub 20240313. doi: 10.1152/ajpendo.00294.2023. PubMed PMID: 38477665.

6. Morissette A, de Wouters d'Oplinter A, Andre DM, Lavoie M, Marcotte B, Varin TV, et al. Rebaudioside D decreases adiposity and hepatic lipid accumulation in a mouse model of obesity. Sci Rep. 2024;14(1):3077. Epub 20240206. doi: 10.1038/s41598-024-53587-y. PubMed PMID: 38321177; PubMed Central PMCID: PMC10847429.

7. Morrow NM, Morissette A, Mulvihill EE. Immunomodulation and Inflammation: Role of GLP-1R and GIPR Expressing Cells Within the Gut. Peptides. 2024:171200. Epub 20240328. doi: 10.1016/j.peptides.2024.171200. PubMed PMID: 38555054.

8. Morissette A, Mulvihill EE. Obesity Management for the Treatment of Type 2 Diabetes: Emerging Evidence and Therapeutic Approaches. In Press in the Journal of Pharmacy & Pharmaceutical Sciences

9. Mullur N*, Morissette A*, Morrow N, Mulvihill EE. Incretin Therapies and Cardiovascular Risk in Diabetes and Obesity: A Review of Mechanisms. In press in the Journal of Endocrinology.

Manuscripts in press or in review

1. Morissette A.*,Agrinier, A-L.*, Gignac, T., Ramadan, L., Marois, J., Varin, T.V., Pilon, G., Larose, E., Gagnon, C., Arsenault, B.J., Després, J-P., Carreau, A-M., Vohl, M-C., Marette, A. Substituting refined sugars by maple syrup decreases key cardiometabolic risk factors in individuals with mild metabolic alterations: a randomized, double-blind, controlled crossover trial. Submitted to the Journal of Nutrition. Under revision in the Journal of Nutrition. *Contributed equally.

2. Agrinier, A-L*., Morissette, A*., Daoust, L., Gignac, T., Marois, J., Varin, T.V., Pilon, G., Larose, E., Gagnon, C., Desjardins, Y., Anhê, F.F., Carreau, A-M., Vohl, M-C., Marette, A. Camu-Camu (Myrciaria dubia) decreases hepatic steatosis and improves circulating markers of liver injury in individuals with overweight and hypertriglyceridemia: a randomized, double-blind, placebo-controlled crossover trial. Under revision in Cell Reports Medicine. Under revision. *Contributed equally.

3. Gignac, T., Morissette, A., Agrinier, A-L., Marois, J., Pilon, G., Gagnon, C., Vohl, M-C., Marette, A., Carreau, A-M. Post-OGTT Low Blood Glucose in Individuals with Metabolic Alterations- Mechanisms and Metabolic-Associated Liver Disease. Submitted to Obesity. Under revision in the American Journal of Physiology and Endocrinology.

4. Morissette A, Mulvihill EE. Cardioprotective Benefits of Weight Loss and GLP-1 Receptor Agonsit-Based Therapies in patients with Diabetes. Under revision in the journal Trends in Endocrinology and Metabolism.